| Symbol | PDSB |
|---|---|
| Name | PDS BIOTECHNOLOGY CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 303A COLLEGE ROAD EAST, PRINCETON, NJ 08540 |
| Telephone | 800-208-3343 |
| Fax | — |
| — | |
| Website | https://www.pdsbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001472091 |
| Description | PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. Additional info from NASDAQ: |
(99% Neutral) PDS BIOTECHNOLOGY CORP (PDSB) Announces Executive Departure
Read more(99% Neutral) PDS BIOTECHNOLOGY CORP (PDSB) Announces New Board Appointment
Read more(30% Negative) PDS BIOTECHNOLOGY CORP (PDSB) Reports Q3 2026 Financial Results
Read more(85% Positive) PDS BIOTECHNOLOGY CORP (PDSB) Announces Enrollment Update for opportunities Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read morePDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head … | Phase3 | Recurrent Head and Neck Cancer | Active_Not_Recruiting | 2025-05-30 | 2029-02-01 | ClinicalTrials.gov |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Rec… | Phase2 | Metastatic Head and Neck Cancer | Completed | 2021-03-29 | 2025-05-14 | ClinicalTrials.gov |
| NCT02065973 | An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerabil… | Phase1 | High-risk HPV Infection and Biopsy-proven CIN1 | Completed | 2014-02-01 | 2015-12-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | Other | Phase PHASE1 | High-risk HPV Infection and Biopsy-proven CIN1 | COMPLETED | NCT02065973 |
| Pembrolizumab (KEYTRUDA®) and PDS0101 | Other | Phase PHASE2 | Metastatic Head and Neck Cancer | COMPLETED | NCT04260126 |
| Pembrolizumab Monotherapy | Drug | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| Combination Treatment of PDS0101 and Pembrolizumab | Drug | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| Pembrolizumab Monotherapy | DRUG | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | BIOLOGICAL | Phase PHASE1 | High-risk HPV Infection and Biopsy-proven CIN1 | COMPLETED | NCT02065973 |